USRE44159E1 - Composition for contraception - Google Patents
Composition for contraception Download PDFInfo
- Publication number
- USRE44159E1 USRE44159E1 US11/892,969 US89296907A USRE44159E US RE44159 E1 USRE44159 E1 US RE44159E1 US 89296907 A US89296907 A US 89296907A US RE44159 E USRE44159 E US RE44159E
- Authority
- US
- United States
- Prior art keywords
- days
- pill
- drospirenone
- composition
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the common use of estrogens and gestagens for the production of a combination preparation for oral contraception and a corresponding pack containing this combination preparation.
- Combination preparations for oral contraception are already known, for example, Femovan® [DE-PS 2 546 062] or Marvelon® [DE-OS 2 361 120]. These preparations consist of 21 active ingredient-containing (estrogen/gestagen) dosage units and 7 active ingredient-free coated tablets (sugar pills; placebos). The dose to be administered daily is uniformly high in each case (so-called single-phase preparations) and produces the desired contraceptive effect in the entire intake period and in the intake pause or during the intake of the placebos. In most preparations, a 7-day interruption of the intake of active ingredient-containing dosage units was considered necessary until quite recently to trigger a reliable withdrawal bleeding and thus to achieve a satisfactory cycle control.
- a combination preparation for substitution therapy and contraception for females before menopause is known from EP-A-0 253 607.
- This combination preparation contains an estrogen from the group
- a thus selected composition is to offset hormonal irregularities in the transition phase of premenopause and to help alleviate the symptoms caused by the hormonal changeover of the female organism in this phase.
- Such a composition simultaneously assures a premenopausal female the contraceptive protection still necessary at this age.
- the lowest estrogen dose contained in an oral contraceptive on the market at this time is 20 ⁇ g of ethinylestradiol, combined with 150 ⁇ g of desogestrel (Mercilon).
- desogestrel Mercilon
- the cycle control of this preparation is, as expected, somewhat poorer in comparison to preparations with a higher estrogen dose, the high acceptance rate of Mercilon indicates a small clinical relevance of this drawback.
- the observation, made identically in several studies, of a lesser ovarial suppression of the preparation containing 20 ⁇ g of ethinylestradiol represents a clinically important problem.
- the object of this invention is an improved single-phase combination preparation for a female of reproductive age, who is not yet in premenopause, containing an estrogen and gestagen in each individual dosage unit, with the lowest possible estrogen content in each individual dosage unit, but also with a low total hormone content per administration cycle.
- premenopause and “menopause” are used within the scope of this invention in the meaning of the conventional definition, see, for example, “The Controversial Climacteric,” P. A. of Keep et al., Ed., MTP press (1981), e.g., p. 9.
- the daily hormone dose is kept to a very low level here, while the usual 21-day intake is extended by two or three days.
- the remaining 5 or 4 days of a cycle are preferably bridged over by placebos, to avoid intake errors, or by 5 or 4 intake-free days.
- this relates to the use of a composition comprising an estrogen selected from
- this invention relates to a combination product for oral contraception, which comprises
- An especially preferred combination preparation according to this invention comprises 23 dosage units, each containing 20 ⁇ g of ethinylestradiol and 75 ⁇ g of gestodene and 5 sugar pills or other indications to show that no dosage unit or a sugar pill is administered during the last 5 days of the menstrual cycle.
- the ovarian suppression was measured based on the level of the endogenous 17 ⁇ -estradiol level and the size of follicular structures. The results show that the 17 ⁇ -estradiol levels with 23-day intake of the test preparation were significantly lower (p ⁇ 0.05) in comparison to the 21-day administration ( FIG. 1 ).
- the combination preparation according to the invention thus achieves the effectiveness previously known for preparations with a daily content of 30 ⁇ g of ethinylestradiol, although the daily ethinylestradiol dose is 33% lower and also the total dose per cycle is 27% lower.
- the endogenous 17 ⁇ -estradiol levels are suppressed easily controllably in the case of the majority of the users of the 23-day preparation.
- Clinical symptoms such as breast tenseness, premenstrual syndrome and menstrual disorders, which can be attributed to increased and greatly fluctuating estrogen levels, are observed with the 23-day preparation with clearly lower frequency.
- an intake, extended by two (or three) days, of preparations containing 20 ⁇ g of ethinylestradiol in each daily dosage unit can produce the above-mentioned advantages, without the daily dose having to be raised to the previously largely used level of 30 ⁇ g of ethinylestradiol.
- an estrogen and gestagen for the use according to the invention or for a combination preparation according to the invention takes place completely analogously as it is already known for usual oral contraceptives with 21-day intake period of the active ingredients, such as, for example, Femovan® (ethinylestradiol/gestodene) or Microgynon® (ethinylestradiol/levonorgestrel).
- active ingredients such as, for example, Femovan® (ethinylestradiol/gestodene) or Microgynon® (ethinylestradiol/levonorgestrel).
- a pack containing a combination preparation according to the invention is also designed analogously to packs for already known oral contraceptives on the market with the variation that instead of the usual 21 dosage units containing the active components, now 23 or 24 such dosage units and 5 or 4 sugar pills are present or else contain other suitable indications that 5 or 4 days are to be bridged over until continuation of the intake of active ingredient-containing dosage units.
- EP-A 0 253 607 especially also to the statements there for determination of equivalent amounts of ethinylestradiol and 17 ⁇ -estradiol, on the one hand, and various gestagens, such as levonorgestrel, desogestrel, 3-ketodesogestrel and gestodene, on the other hand.
- FIG. 1 Area with the 17 ⁇ -estradiol level in groups of 30 females, who are treated with an oral contraceptive (75 ⁇ g of gestodene+20 ⁇ g of ethinylestradiol) in 21- or 23-day administration interval over three cycles.
- FIG. 2 Number of females in %, who showed follicular developments (>13 mm diameter) with 21- or 23-day treatment with an oral contraceptive (75 ⁇ g of gestodene+20 ⁇ g of ethinylestradiol).
Abstract
A combination product for oral contraception is disclosed comprising an estrogen selected from
-
- 2.0 to 6.0 mg of 17β-estradiol and
- 0.020 mg of ethinylestradiol;
and a gestagen selected from - 0.25 to 0.30 mg of drospirenone and
- 0.1 to 0.2 mg of cyproterone acetate,
followed by 5 or 4 pill-free or sugar pill days.
Description
ThisNotice: More than one reissue application has been filed for the reissue of U.S. Pat. No. 5,824,667: this Ser. No. 11/892,969 continuation reissue application is a divisional of reissue application Ser. No. 10/916,600 of Aug. 12, 2004 now abandoned, which is a continuation of reissue application Ser. No. 10/193,758 filed Jul. 12, 2002, now abandoned, which is a continuation of reissue application Ser. No. 09/504,084, filed Feb. 15, 2000, now U.S. Pat. No. Re. 37,838, which is a reissue of application Ser. No. 08/742,147, filed Oct. 31, 1996, now U.S. Pat. No. 5,824,667, which is a continuation of the application Ser. No. 08/268,996 filed Jun. 30, 1994, now U.S. Pat. No. 5,583,129; and reissue application Ser. No. 10/080,617, filed on Feb. 25, 2002, now U.S. Pat. No. Re. 38,253, is a continuation of reissue application Ser. No. 09/503,952, now U.S. Pat. No. Re. 37,564, which also is a reissue of application Ser. No. 08/742,147, filed Oct. 31, 1996, now U.S. Pat. No. 5,824,667, which is a continuation of the application Ser. No. 08/268,996, filed Jun. 30, 1994, now U.S. Pat. No. 5,583,129; and a continuation reissue application of Ser. No. 10/916,600 has been filed, on Mar. 24, 2006, having Ser. No. 11/388,172.
This invention relates to the common use of estrogens and gestagens for the production of a combination preparation for oral contraception and a corresponding pack containing this combination preparation.
Combination preparations for oral contraception are already known, for example, Femovan® [DE-PS 2 546 062] or Marvelon® [DE-OS 2 361 120]. These preparations consist of 21 active ingredient-containing (estrogen/gestagen) dosage units and 7 active ingredient-free coated tablets (sugar pills; placebos). The dose to be administered daily is uniformly high in each case (so-called single-phase preparations) and produces the desired contraceptive effect in the entire intake period and in the intake pause or during the intake of the placebos. In most preparations, a 7-day interruption of the intake of active ingredient-containing dosage units was considered necessary until quite recently to trigger a reliable withdrawal bleeding and thus to achieve a satisfactory cycle control.
Other preparations, which exhibit more than 21 dosage units containing an estrogenic and progestational active ingredient, and in which the intake pause is partially (Ijzerman, Pasquale) or completely (Kuhl) bridged over by estrogen-containing dosage units. In this case, it is possible that the synthetic estrogen ethinylestradiol otherwise contained in oral contraceptives is replaced partially or completely by a conjugated estrogen, preferably estradiol.
A combination preparation for substitution therapy and contraception for females before menopause (approximately starting from the 40th year of life) is known from EP-A-0 253 607. This combination preparation contains an estrogen from the group
-
- 17β-Estradiol,
- ethinylestradiol and
- mestranol
as well as a gestagen from the group - levonorgestrel,
- gestodene,
- desogestrel,
- 3-ketodesogestrel and
- norethindrone.
A thus selected composition is to offset hormonal irregularities in the transition phase of premenopause and to help alleviate the symptoms caused by the hormonal changeover of the female organism in this phase. Such a composition simultaneously assures a premenopausal female the contraceptive protection still necessary at this age.
The development of new oral contraceptives for females of reproductive age before premenopause was characterized during the last twenty years above all by the reduction of the estrogen and gestagen dosages.
The reduction of the daily hormone dose was connected with the expectation to minimize the frequency of undesired side effects. Epidemiological data collected in the meantime confirm the desired trend toward better compatibility of lower-dosed preparations relative to cardiovascular complications [(1.) Thorogood, M., Oral Contraceptives and Cardiovascular Disease: An Epidemiologic Overview; Pharmacoepidemiology and Drug Safety, Vol. 2: 3-16 (1993); (2.) Gerstman, B. B.; Piper, J. M.; Tomita, D. K.; Ferguson, W. J.; Stadel, B. V.; Lundin, F. E.; Oral Contraceptive Estrogen Dose and the Risk of Deep Venous Thromboembolic Disease, Am. J. E., Vol. 133, No. 1, 32-36 (1991); (3.) Lidegaard, O., Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study; BMJ Vol. 306, 956-63 (1993); (4.) Vessey, M.; Mant, D.; Smith, A.; Yeates, D.; Oral contraceptives and venous thromboembolism: findings in a large prospective study; BMJ, Vol. 292, (1986); (5.) Mishell, D. R., Oral Contraception: Past, Present and Future Perspectives; Int. J. Fertil., 36 Suppl., 7-18 (1991)].
It is assumed that a correlation exists above all between the level of the estrogen dose and the incidence of cardiovascular diseases. But the maintenance of the contraceptive effectiveness stands in the way of an extreme reduction of the daily estrogen dose. Although the ovulation-inhibiting effect of the low-dosed oral contraceptives is caused mainly by the gestagenic component, the estrogenic component also makes a significant contribution to the central inhibition action and to the ovarian suppression (ovulation inhibition). Moreover, the daily estrogen dose must not fall below the minimum dose ranges, so that a satisfactory cycle control can be assured (Der Frauenarzt [The Gynecologist]; 34, 7: 793 (1993)].
The lowest estrogen dose contained in an oral contraceptive on the market at this time is 20 μg of ethinylestradiol, combined with 150 μg of desogestrel (Mercilon). Although the cycle control of this preparation is, as expected, somewhat poorer in comparison to preparations with a higher estrogen dose, the high acceptance rate of Mercilon indicates a small clinical relevance of this drawback. But the observation, made identically in several studies, of a lesser ovarial suppression of the preparation containing 20 μg of ethinylestradiol represents a clinically important problem. Obviously with this very low estrogen dose, in the case of many females, the maturation of follicles, which could be detected with ultrasonic studies or hormonal studies, results [(6.) Lunell, N. O.; Carlström, K.; Zador, G.; Ovulation inhibition with a combined oral contraceptive containing 20 μg of ethinylestradiol and 250 μg of levonorgestrel; Acta. Obstet. Gynecol. Scand. Suppl. 88: 17-21 (1979); (7.) Mall-Haefeli, M.; Werner-Zodrow, I.; Huber, P. R.; Klinische Erfahrungen mit Mercilon und Marvelon unter besonderer Berücksichtigung der Ovar-Funktion [Clinical Experience with Mercilon and Marvelon under special consideration of the ovary function]; Geburtsh. und Frauenheilk. [Obstetrics and Gynecology] 51, 35-38, Georg Thieme Verlag, Stuttgart-New York (1991); (8.) Strobel, E., Behandlung mit oralen Kontrazeptiva [Treatment with Oral Contraceptives]; Fortschr. Med. Vol. 110, No. 20 (1992); (9.) Letter to Editor, Contraception 45: 519-521 (1992); (10.) Teichmann, A. T.; Brill, K.; Can Dose Reduction of Ethinylestradiol in OCs Jeopardize Ovarian Suppression and Cycle Control? Abstract Book, VIIIth World Congress on Human Reproduction, Bali, Indonesia (1993)].
The hormone determinations performed showed that functional granulosa cells that secrete 17β-estradiol are involved. Each intake error in the case of females with clear ovarian activity, thus with follicular maturations, can result in a quick increase of gonadotropin production. The requirements for an ovulation would thus be present. It is estimated that approximately one third of females take oral contraceptives irregularly within one year of use (Gynpress, Volume 1, No. 3, 1990). The risk of a pregnancy is therefore high especially in the case of intake errors with the 20 μg ethinylestradiol preparations.
The object of this invention is an improved single-phase combination preparation for a female of reproductive age, who is not yet in premenopause, containing an estrogen and gestagen in each individual dosage unit, with the lowest possible estrogen content in each individual dosage unit, but also with a low total hormone content per administration cycle.
It has now been found that a pronounced ovarian suppression without frequent follicular maturations with low daily estrogen dosage, low total estrogen as well as low total hormone amount per administration cycle can be achieved by the use of a composition comprising an estrogen selected from
-
- 2.0 to 6.0 mg of 17β-estradiol and
- 0.015 to 0.020 mg of ethinylestradiol;
and a gestagen selected from - 0.05 to 0.075 mg of gestodene,
- 0.075 to 0.125 mg of levonorgestrel,
- 0.06 to 0.15 mg of desogestrel,
- 0.06 to 0.15 mg of 3-ketodesogestrel,
- 0.1 to 0.31 to 3 mg of drospirenone,
- 0.1 to 0.21 to 2 mg of cyproterone acetate,
- 0.2 to 0.3 mg of norgestimate and
- >0.35 to 0.75 mg of norethisterone.
for the production of a form of dosage for contraception for a female of reproductive age, who has not yet reached premenopause, by administration of the form of dosage for 23 or 24 days, beginning on day one of the menstrual cycle (first day of menstrual bleeding), followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
The terms “premenopause” and “menopause” are used within the scope of this invention in the meaning of the conventional definition, see, for example, “The Controversial Climacteric,” P. A. of Keep et al., Ed., MTP press (1981), e.g., p. 9.
The daily hormone dose is kept to a very low level here, while the usual 21-day intake is extended by two or three days. The remaining 5 or 4 days of a cycle are preferably bridged over by placebos, to avoid intake errors, or by 5 or 4 intake-free days.
According to a preferred embodiment of this invention, this relates to the use of a composition comprising an estrogen selected from
-
- >2.0 to 6.0 mg of 17β-estradiol and
- 0.020 mg of ethinylestradiol;
and a gestagen selected from - >0.06 to 0.075 mg of gestodene,
- >0.100 to 0.125 mg of levonorgestrel,
- >0.10 to 0.15 mg of desogestrel,
- >0.10 to 0.15 mg of 3-ketodesogestrel,
- 0.25 to 0.302.5 to 3.0 mg of drospirenone,
- 0.1 to 0.21 to 2 mg of cyproterone acetate,
- 0.2 to 0.3. mg of norgestimate and
- 0.50 to 0.75 mg of norethisterone
for the production of a form of dosage for contraception as described above.
In addition, this invention relates to a combination product for oral contraception, which comprises
a) 23 or 24 dosage units, each containing an estrogen selected from
-
- >2.0 to 6.0 mg of 17β-estradiol and
- 0.020 mg of ethinylestradiol;
and a gestagen selected from - >0.06 to 0.075 mg of gestodene,
- >0.100 to 0.125 mg of levonorgestrel,
- >0.10 to 0.15 mg of desogestrel,
- >0.10 to 0.15 mg of 3-ketodesogestrel,
- 0.25 to 0.302.5 to 3.0 mg of drospirenone,
- 0.1 to 0.21 to 2 mg of cyproterone acetate,
- 0.2 to 0.3 mg of norgestimate and
- 0.50 to 0.75 mg of norethisterone
and
b) 5 or 4 sugar pills or other indications to show that the daily administration of 23 or 24 dosage units is to be followed by 5 or 4 pill-free or sugar pill days are to be followed.
Further embodiments according to the invention follow from the features of the subclaims.
An especially preferred combination preparation according to this invention comprises 23 dosage units, each containing 20 μg of ethinylestradiol and 75 μg of gestodene and 5 sugar pills or other indications to show that no dosage unit or a sugar pill is administered during the last 5 days of the menstrual cycle.
The clinical study briefly described below was performed with ethinylestradiol as estrogen and gestodene as representative of the substance class of the gestagens possible according to the invention. All possible combinations of ethinylestradiol or estradiol according to the invention in the indicated dosages with one of the selected gestagens in the indicated dosages as 23- or 24-day preparations exhibit the advantages according to the invention.
The 23-day administration of 20 μg of ethinylestradiol in combination with 75 μg of gestodene results, in comparison to the 21-day administration, in a stronger ovarian suppression. In a double-placebo, randomized study on healthy females with normal ovarian function, groups of 30 test subjects each received the combination preparation either once daily over 21 or 23 days as well as placebos on 7 or 5 days (to assure the double-placebo nature of the study).
The treatment began after an ovulatory, untreated preliminary cycle on the first day of the menstrual bleeding of the subsequent cycle and extended altogether over three treatment cycles. The study was concluded with an untreated follow-up cycle.
The ovarian suppression was measured based on the level of the endogenous 17β-estradiol level and the size of follicular structures. The results show that the 17β-estradiol levels with 23-day intake of the test preparation were significantly lower (p<0.05) in comparison to the 21-day administration (FIG. 1 ).
In accordance with this finding, the number of females with follicular maturations was also clearly higher in the 21-time administration relative to the 23-time administration (FIG. 2 ).
The intake interval extended only by two days surprisingly produces a significantly greater ovarian suppression with unchangingly low daily doses. The combination preparation according to the invention thus achieves the effectiveness previously known for preparations with a daily content of 30 μg of ethinylestradiol, although the daily ethinylestradiol dose is 33% lower and also the total dose per cycle is 27% lower.
The advantages of a combination preparation for oral contraception to be administered over 23 days relative to the usual 21-day preparations with less than 30 μg of ethinylestradiol can be characterized as follows:
1. A significantly lower frequency of follicular developments in the user (maximum of 13% in females who received the 23-day preparation relative to a maximum of 40% among those who received the 21-day preparation). This means a greater contraceptive reliability of the 23-day preparation, especially in the case of previous intake errors. The danger of “breakthrough ovulations” is smaller.
2. The occurrence of large follicles of more than a 30 mm diameter is extremely rare. The development of ovarian cysts is improbable with the 23-day preparation in comparison to the 21-day preparation.
3. The recruitment of dominant follicles is suppressed in the shortened intake-free pause.
4. The endogenous 17β-estradiol levels are suppressed easily controllably in the case of the majority of the users of the 23-day preparation. Clinical symptoms such as breast tenseness, premenstrual syndrome and menstrual disorders, which can be attributed to increased and greatly fluctuating estrogen levels, are observed with the 23-day preparation with clearly lower frequency.
In summary, an intake, extended by two (or three) days, of preparations containing 20 μg of ethinylestradiol in each daily dosage unit can produce the above-mentioned advantages, without the daily dose having to be raised to the previously largely used level of 30 μg of ethinylestradiol.
The formulation of an estrogen and gestagen for the use according to the invention or for a combination preparation according to the invention takes place completely analogously as it is already known for usual oral contraceptives with 21-day intake period of the active ingredients, such as, for example, Femovan® (ethinylestradiol/gestodene) or Microgynon® (ethinylestradiol/levonorgestrel).
A pack containing a combination preparation according to the invention is also designed analogously to packs for already known oral contraceptives on the market with the variation that instead of the usual 21 dosage units containing the active components, now 23 or 24 such dosage units and 5 or 4 sugar pills are present or else contain other suitable indications that 5 or 4 days are to be bridged over until continuation of the intake of active ingredient-containing dosage units.
Moreover, reference is made to the statements made in EP-A 0 253 607, especially also to the statements there for determination of equivalent amounts of ethinylestradiol and 17β-estradiol, on the one hand, and various gestagens, such as levonorgestrel, desogestrel, 3-ketodesogestrel and gestodene, on the other hand.
For further details for the determination of dose equivalents of various gestagenic active ingredients, reference is made to “Probleme der Dosisfindung: Sexualhormone” [Problems of Dose-Finding: Sex Hormones]; F. Neumann et al. in “Arzneimittelforschung” (Pharmaceutical Agent Research) 27, 2a, 296-318 (1977), as well as to “Aktuelle Entwicklungen in der hormonalen Kontrazeption” [Current Developments in Hormonal Contraception]; H. Kuhl in Gynäkologe” [Gynecologist) 25: 231-240 (1992).
Claims (28)
1. A combination product for oral contraception, comprising
(a) 23 or 24 dosage units, each containing an estrogen selected from
>2.0 to 6.0 mg of 17β-estradiol and
0.020 mg of ethinylestradiol;
and a gestagen selected from
0.25 to 0.30 mg of drospirenone and
0.1 to 0.2 mg of cyproterone acetate,
and
b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days.
2. A combination preparation for oral contraception according to claim 1 , wherein the estrogen is ethinylestradiol.
3. A combination preparation of claim 2 , wherein the gestagen is cyproterone acetate.
4. A combination preparation of claim 2 , wherein the gestagen is drospirenone.
5. A combination preparation according to claim 1 , wherein the estrogen is present in a dose of 20 μg of ethinylestradiol or an equivalent dose of 17β-estradiol and the gestagen is present in a dose equivalent to 75 μg of gestadene.
6. A combination preparation according to claim 1 , which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle.
7. A combination preparation according to claim 1 , which comprises 23 dosage units, each containing 20 μg of ethinylestradiol and a dose of cyproterone acetate or drospirenone equivalent to 75 μg of gestodene and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle.
8. A combination preparation of claim 1 , wherein the estrogen is 17β-estradiol.
9. A combination preparation of claim 8 , wherein the gestagen is cyproterone acetate.
10. A combination preparation of claim 8 , wherein the gestagen is drospirenone.
11. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female a monophasic composition that effectively lessens premenstrual syndrome, comprising 0.015 to 0.020 mg of ethynylestradiol and 1-3 mg of drospirenone, wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
12. A method of claim 11 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
13. A method of claim 12 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
14. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female a monophasic composition that effectively lessens breast tenderness, comprising 0.015 to 0.020 mg of ethynylestradiol and 1-3 mg of drospirenone, wherein the composition effectively lessens breast tenderness, and is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
15. A method of claim 14 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
16. A method of claim 15 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
17. A method of claim 11 wherein the composition effectively lessens breast tenderness.
18. A method of claim 17 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
19. A method of claim 18 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
20. A method of inducing contraception in a female of reproductive age suffering from premenstrual syndrome who has not yet reached premenopause, comprising administering to said female a monophasic composition comprising 0.015 to 0.020 mg of ethynylestradiol and 1-3 mg of drospirenone, wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
21. A method of claim 20 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
22. A method of claim 21 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
23. A method of inducing contraception in a female of reproductive age suffering from breast tenderness who has not yet reached premenopause, comprising administering to said female a monophasic composition comprising 0.015 to 0.020 mg of ethynylestradiol and 1-3 mg of drospirenone, wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
24. A method of claim 23 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
25. A method of claim 24 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
26. A method of claim 20 wherein the female of reproductive age suffers from breast tenderness.
27. A method of claim 26 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
28. A method of claim 27 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/388,172 USRE43916E1 (en) | 1993-12-22 | 2006-03-24 | Composition for contraception |
US11/892,969 USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4344462A DE4344462C2 (en) | 1993-12-22 | 1993-12-22 | Composition for contraception |
DEP4344462 | 1993-12-22 | ||
US08/268,996 US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US09/503,952 USRE37564E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US09/504,084 USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US10/080,617 USRE38253E1 (en) | 1993-12-22 | 2002-02-25 | Composition for contraception |
US19375802A | 2002-07-12 | 2002-07-12 | |
US91660004A | 2004-08-12 | 2004-08-12 | |
US11/892,969 USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/742,147 Reissue US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US09/503,952 Continuation USRE37564E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/504,084 Continuation USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE44159E1 true USRE44159E1 (en) | 2013-04-16 |
Family
ID=6506206
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/268,996 Expired - Lifetime US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 Ceased US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US09/503,952 Expired - Lifetime USRE37564E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US09/504,084 Expired - Lifetime USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US10/080,617 Expired - Lifetime USRE38253E1 (en) | 1993-12-22 | 2002-02-25 | Composition for contraception |
US11/388,172 Expired - Lifetime USRE43916E1 (en) | 1993-12-22 | 2006-03-24 | Composition for contraception |
US11/892,969 Expired - Lifetime USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/268,996 Expired - Lifetime US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 Ceased US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US09/503,952 Expired - Lifetime USRE37564E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US09/504,084 Expired - Lifetime USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US10/080,617 Expired - Lifetime USRE38253E1 (en) | 1993-12-22 | 2002-02-25 | Composition for contraception |
US11/388,172 Expired - Lifetime USRE43916E1 (en) | 1993-12-22 | 2006-03-24 | Composition for contraception |
Country Status (21)
Country | Link |
---|---|
US (7) | US5583129A (en) |
EP (2) | EP0735883B1 (en) |
JP (4) | JPH09506888A (en) |
KR (1) | KR100369206B1 (en) |
CN (2) | CN100377713C (en) |
AT (1) | ATE344038T1 (en) |
CA (1) | CA2179728C (en) |
CZ (1) | CZ296387B6 (en) |
DE (2) | DE4344462C2 (en) |
DK (1) | DK0735883T3 (en) |
ES (1) | ES2276391T3 (en) |
HK (1) | HK1077743A1 (en) |
HU (1) | HUT74877A (en) |
NL (1) | NL300329I1 (en) |
NO (1) | NO316257B1 (en) |
NZ (1) | NZ278058A (en) |
PL (1) | PL187818B1 (en) |
PT (1) | PT735883E (en) |
RU (1) | RU2169567C2 (en) |
SK (1) | SK285965B6 (en) |
WO (1) | WO1995017194A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11376263B2 (en) | 2020-10-08 | 2022-07-05 | Fortress Biotech, Inc. | Cyproterone acetate compositions and uses thereof |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4344462C2 (en) | 1993-12-22 | 1996-02-01 | Schering Ag | Composition for contraception |
US6309843B1 (en) | 1994-10-25 | 2001-10-30 | The Curators Of The University Of Missouri | Glycoprotein for use in determining endometrial receptivity |
PT792152E (en) * | 1994-11-22 | 2004-07-30 | Balance Pharmaceuticals Inc | METHODS OF CONTRACEPTION |
DE19513662A1 (en) * | 1995-04-08 | 1996-10-10 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
DE19540253C2 (en) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Multi-phase preparation for contraception based on natural estrogens |
WO1997041872A1 (en) * | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
US5747480A (en) * | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
EP0921804B1 (en) * | 1996-07-26 | 2003-09-10 | Wyeth | Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen |
EP0956024B1 (en) * | 1996-07-26 | 2004-07-21 | Wyeth | Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen |
US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
WO1998004267A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
IL127923A (en) * | 1996-07-26 | 2004-07-25 | Wyeth Corp | Oral contraceptive |
US6479475B1 (en) | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
US6451778B1 (en) | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
WO2001030355A1 (en) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Contraceptive medicine based on a progestational agent and an oestrogen and preparation method |
FR2754179B1 (en) * | 1996-10-08 | 1998-12-24 | Theramex | NOVEL HORMONONAL COMPOSITION AND ITS USE |
US6987101B1 (en) * | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
DE19654609A1 (en) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutic progestogens for the treatment of premenstrual dysphoric disorder |
US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
DE122009000006I2 (en) * | 1999-08-31 | 2012-03-22 | Bayer Schering Pharma | Pharmaceutical combination of ethinyl estradiol and drospirenone as a contraceptive agent. |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
RU2269342C9 (en) * | 1999-08-31 | 2007-10-27 | Шеринг Акциенгезелльшафт | Pharmaceutical combination of ethynylestradiol and drospirenone for using as contraceptive |
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
US7025979B2 (en) * | 2000-02-15 | 2006-04-11 | Schering Ag | Male contraceptive formulation comprising norethisterone |
US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
DE10045380A1 (en) * | 2000-09-14 | 2002-04-04 | Schering Ag | Contraception procedure and dosage form |
EP1216712A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
US20060142257A1 (en) * | 2001-01-19 | 2006-06-29 | Eberhard Nieschlag | Male contraceptive formulation comprising norethisterone |
WO2003006027A1 (en) * | 2001-07-13 | 2003-01-23 | Schering Aktiengesellschaft | Combination of drospirenone and an estrogen sulphamate for hrt |
RU2351339C2 (en) | 2001-12-05 | 2009-04-10 | Дюрамед Фармасьютикалс, Инк. | Oral contraceptives for prevention pregnancy and reduction of premenstrual symptomatology |
US6962908B2 (en) | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
AU2003239162A1 (en) * | 2002-04-26 | 2003-11-10 | Schering Ag | Treatment of hypertension in women receiving hormone replacement therapy |
US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
WO2004098517A2 (en) * | 2003-05-02 | 2004-11-18 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
CA2771944A1 (en) * | 2003-07-16 | 2005-01-27 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
DE102004019743B4 (en) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Multiphase preparation for contraception based on natural estrogen |
MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
DE102004026670A1 (en) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate |
US8501720B2 (en) * | 2004-07-30 | 2013-08-06 | Bayer Pharma AG | Method for treatment of dysmenorrhea |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
EP1868593A2 (en) * | 2005-04-07 | 2007-12-26 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
TW200744610A (en) * | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
US8153616B2 (en) * | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (en) * | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido |
AR065816A1 (en) * | 2007-03-26 | 2009-07-01 | Theramex | ORAL CONTRACEPTIVE REGIME |
DE102007027636A1 (en) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17β-Cyano-18α-homo-19-nor-androst-4-ene derivative, its use and the derivative-containing drug |
DE102007027637A1 (en) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17β-cyano-19-nor-androst-4-ene derivative, its use and the derivative-containing drug |
CN102123938A (en) | 2007-09-06 | 2011-07-13 | 可口可乐公司 | Systems and methods for providing portion control programming in a product forming dispenser |
BRPI0816482A2 (en) | 2007-09-06 | 2015-03-17 | Coca Cola Co | Methods for dispensing a product and an ingredient of the product, and dispensing apparatus |
CA2740005C (en) | 2008-10-08 | 2016-11-01 | Agile Therapeutics, Inc. | Transdermal delivery |
WO2010042610A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
CA2740002C (en) | 2008-10-08 | 2016-11-01 | Agile Therapeutics, Inc. | Transdermal delivery |
US9198920B2 (en) | 2009-03-27 | 2015-12-01 | Agile Therapeutics, Inc. | Contraceptive transdermal delivery of hormones |
US10192037B2 (en) | 2011-08-26 | 2019-01-29 | Elwah LLC | Reporting system and method for ingestible product preparation system and method |
US8989895B2 (en) | 2011-08-26 | 2015-03-24 | Elwha, Llc | Substance control system and method for dispensing systems |
US9997006B2 (en) | 2011-08-26 | 2018-06-12 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
US9111256B2 (en) | 2011-08-26 | 2015-08-18 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
US8892249B2 (en) | 2011-08-26 | 2014-11-18 | Elwha Llc | Substance control system and method for dispensing systems |
US20130054255A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Controlled substance authorization and method for ingestible product preparation system and method |
US10121218B2 (en) | 2012-06-12 | 2018-11-06 | Elwha Llc | Substrate structure injection treatment system and method for ingestible product system and method |
US9240028B2 (en) | 2011-08-26 | 2016-01-19 | Elwha Llc | Reporting system and method for ingestible product preparation system and method |
US9037478B2 (en) | 2011-08-26 | 2015-05-19 | Elwha Llc | Substance allocation system and method for ingestible product preparation system and method |
US20130330451A1 (en) | 2012-06-12 | 2013-12-12 | Elwha LLC, a limited liability company of the State of Delaware | Substrate Structure Duct Treatment System and Method for Ingestible Product System and Method |
US9785985B2 (en) | 2011-08-26 | 2017-10-10 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
US10026336B2 (en) | 2011-08-26 | 2018-07-17 | Elwha Llc | Refuse intelligence acquisition system and method for ingestible product preparation system and method |
US9947167B2 (en) | 2011-08-26 | 2018-04-17 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
US9922576B2 (en) | 2011-08-26 | 2018-03-20 | Elwha Llc | Ingestion intelligence acquisition system and method for ingestible material preparation system and method |
US20130331981A1 (en) | 2012-06-12 | 2013-12-12 | Elwha LLC, a limited liability company of the State of Delaware | Substrate Structure Deposition Treatment System And Method For Ingestible Product System And Method |
US20140122120A1 (en) * | 2012-10-30 | 2014-05-01 | Pacesetter, Inc. | Systems and methods for providing photo-based patient verification for use with implantable medical device programmers |
CN104546870B (en) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | A kind of contraceptive |
RU2664437C2 (en) * | 2016-09-29 | 2018-08-17 | Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" | Means of prolonged action on the basis of proligestone to suppress estrus in small animals |
CN110548034A (en) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | Pregnancy-blocking medicine |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639600A (en) | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
US3932635A (en) | 1972-04-24 | 1976-01-13 | Syntex Corporation | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens |
US3939264A (en) | 1972-04-14 | 1976-02-17 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
US3969502A (en) | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
US4129564A (en) | 1976-11-16 | 1978-12-12 | Schering, A.G. Patentabteilung | Spirolactones |
US4145416A (en) | 1976-06-23 | 1979-03-20 | Schering, A.G. | Novel agents and novel methods for treatment of climacteric disturbances |
DE3022337A1 (en) | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Compsns. for contraception or treatment of gynaecological disorders - contg. 6 beta, 7 beta; 15 delta, 16 beta-di:methylene-3-oxo-4-androstene-17(beta-1')-spiro-5'-per:hyd- ro-furan-2'-one |
EP0253607A1 (en) | 1986-07-15 | 1988-01-20 | American Home Products Corporation | Combination dosage form for premenopausal women |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
US4904462A (en) | 1984-04-13 | 1990-02-27 | Schering Aktiengesellschaft | Multiply-tritiated steroidal-20,17-spirolactones and their use as tracer compounds |
CA2016780A1 (en) | 1989-05-16 | 1990-11-16 | Sybille Beier | Dihydrospirorenone as an antiandrogen |
US5010070A (en) | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
US5098714A (en) | 1989-11-16 | 1992-03-24 | Alza Corporation | Osmotic, oral dosage form for fertility control |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
EP0491415A1 (en) | 1990-12-13 | 1992-06-24 | Akzo Nobel N.V. | Low estrogen oral contraceptives |
EP0491438A1 (en) | 1990-12-17 | 1992-06-24 | Akzo Nobel N.V. | Contraceptive regimen |
US5208225A (en) | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
US5256421A (en) | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
US5340584A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders |
EP0640343A1 (en) | 1993-07-01 | 1995-03-01 | Leiras Oy | Contraceptive for oral use containing oestradial valerate and cyproterone acetate |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
DE4344462A1 (en) | 1993-12-22 | 1995-06-29 | Schering Ag | Composition for contraception |
DE4411585A1 (en) | 1994-03-30 | 1995-10-05 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
US5552394A (en) | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
EP0814803A2 (en) | 1995-03-16 | 1998-01-07 | Schering Aktiengesellschaft | Use of anti-oestrogens as male contraceptives |
WO1998004265A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004268A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Oral contraceptive |
WO1998004246A2 (en) | 1996-07-26 | 1998-02-05 | American Home Prod | Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004269A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004267A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
EP1334725A2 (en) | 1996-10-08 | 2003-08-13 | Laboratoire Theramex | Estroprogestative contraceptive composition |
EP1462107A1 (en) | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Method of female contraception and kit for use in such method |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI54128C (en) | 1972-12-09 | 1978-10-10 | Akzo Nv | FREQUENCY REFRIGERATION FOR NY 11,11-ALKYLIDENSTEROIDER UR OESTRAN- OCH 19-NORPREGNANSERIEN MED FOERBAETTRAD HORMONELL VERKAN |
DE2546062A1 (en) | 1975-10-10 | 1977-04-21 | Schering Ag | (17)-Alkynyl-(17)-hydroxy-(4,15)-oestradienones and derivs. - progestational agents inhibiting ovulation and implantation |
DE3023233C2 (en) | 1980-06-21 | 1982-04-08 | Berg & Co Gmbh, 4800 Bielefeld | Pressure medium distributor for rotating clamping cylinders with clamping pistons that can be axially displaced therein on machine tools, in particular multi-spindle lathes |
AU582540B2 (en) * | 1983-08-05 | 1989-04-06 | Pre Jay Holdings Ltd. | A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor |
US4616006A (en) * | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
DK174071B1 (en) * | 1987-09-24 | 2002-05-21 | Jencap Res Ltd | Contraceptive preparation in the form of a package comprising unit doses |
-
1993
- 1993-12-22 DE DE4344462A patent/DE4344462C2/en not_active Expired - Lifetime
-
1994
- 1994-06-30 US US08/268,996 patent/US5583129A/en not_active Expired - Lifetime
- 1994-12-22 JP JP7517199A patent/JPH09506888A/en not_active Withdrawn
- 1994-12-22 PL PL94315168A patent/PL187818B1/en unknown
- 1994-12-22 EP EP95905574A patent/EP0735883B1/en not_active Revoked
- 1994-12-22 CN CNB2004100590293A patent/CN100377713C/en not_active Ceased
- 1994-12-22 CZ CZ0186196A patent/CZ296387B6/en not_active IP Right Cessation
- 1994-12-22 WO PCT/EP1994/004274 patent/WO1995017194A1/en active IP Right Grant
- 1994-12-22 ES ES95905574T patent/ES2276391T3/en not_active Expired - Lifetime
- 1994-12-22 CA CA002179728A patent/CA2179728C/en not_active Expired - Lifetime
- 1994-12-22 PT PT95905574T patent/PT735883E/en unknown
- 1994-12-22 SK SK831-96A patent/SK285965B6/en not_active IP Right Cessation
- 1994-12-22 DE DE59410444T patent/DE59410444D1/en not_active Expired - Lifetime
- 1994-12-22 KR KR1019960703408A patent/KR100369206B1/en not_active IP Right Cessation
- 1994-12-22 HU HU9601750A patent/HUT74877A/en not_active Application Discontinuation
- 1994-12-22 NZ NZ278058A patent/NZ278058A/en not_active IP Right Cessation
- 1994-12-22 DK DK95905574T patent/DK0735883T3/en active
- 1994-12-22 CN CN94194888A patent/CN1142185A/en active Pending
- 1994-12-22 RU RU96115196/14A patent/RU2169567C2/en active
- 1994-12-22 EP EP06076732A patent/EP1726308A3/en not_active Ceased
- 1994-12-22 AT AT95905574T patent/ATE344038T1/en active
-
1996
- 1996-06-24 NO NO19962676A patent/NO316257B1/en not_active IP Right Cessation
- 1996-10-31 US US08/742,147 patent/US5824667A/en not_active Ceased
-
2000
- 2000-02-15 US US09/503,952 patent/USRE37564E1/en not_active Expired - Lifetime
- 2000-02-15 US US09/504,084 patent/USRE37838E1/en not_active Expired - Lifetime
-
2002
- 2002-02-25 US US10/080,617 patent/USRE38253E1/en not_active Expired - Lifetime
-
2005
- 2005-11-03 HK HK05109807.9A patent/HK1077743A1/en not_active IP Right Cessation
-
2006
- 2006-01-04 JP JP2006000148A patent/JP2006096775A/en not_active Withdrawn
- 2006-03-24 US US11/388,172 patent/USRE43916E1/en not_active Expired - Lifetime
-
2007
- 2007-08-28 US US11/892,969 patent/USRE44159E1/en not_active Expired - Lifetime
-
2008
- 2008-01-07 NL NL300329C patent/NL300329I1/en unknown
-
2010
- 2010-08-06 JP JP2010177241A patent/JP2010248270A/en not_active Withdrawn
-
2013
- 2013-03-13 JP JP2013049933A patent/JP2013139464A/en active Pending
Patent Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639600A (en) | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
US3939264A (en) | 1972-04-14 | 1976-02-17 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
US3969502A (en) | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
US3932635A (en) | 1972-04-24 | 1976-01-13 | Syntex Corporation | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens |
US4145416A (en) | 1976-06-23 | 1979-03-20 | Schering, A.G. | Novel agents and novel methods for treatment of climacteric disturbances |
US4129564A (en) | 1976-11-16 | 1978-12-12 | Schering, A.G. Patentabteilung | Spirolactones |
DE3022337A1 (en) | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Compsns. for contraception or treatment of gynaecological disorders - contg. 6 beta, 7 beta; 15 delta, 16 beta-di:methylene-3-oxo-4-androstene-17(beta-1')-spiro-5'-per:hyd- ro-furan-2'-one |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
US4904462A (en) | 1984-04-13 | 1990-02-27 | Schering Aktiengesellschaft | Multiply-tritiated steroidal-20,17-spirolactones and their use as tracer compounds |
US5208225A (en) | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
WO1988000469A1 (en) | 1986-07-15 | 1988-01-28 | American Home Products Corporation | Combination dosage form for pre-menopausal women |
EP0253607A1 (en) | 1986-07-15 | 1988-01-20 | American Home Products Corporation | Combination dosage form for premenopausal women |
US5010070A (en) | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5256421A (en) | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
CA2016780A1 (en) | 1989-05-16 | 1990-11-16 | Sybille Beier | Dihydrospirorenone as an antiandrogen |
AU5509490A (en) | 1989-05-16 | 1990-11-22 | Schering Aktiengesellschaft | Dihydrospirorenone as an antiandrogen |
EP0398460B1 (en) | 1989-05-16 | 1997-07-02 | Schering Aktiengesellschaft | Use of dihydrospirorenone as an anti-androgen |
US5569652A (en) | 1989-05-16 | 1996-10-29 | Schering Aktiengesellschaft | Dihydrospirorenone as an antiandrogen |
US5098714A (en) | 1989-11-16 | 1992-03-24 | Alza Corporation | Osmotic, oral dosage form for fertility control |
US5262408A (en) | 1990-12-13 | 1993-11-16 | Akzo N.V. | Low estrogen oral contraceptives |
EP0491415A1 (en) | 1990-12-13 | 1992-06-24 | Akzo Nobel N.V. | Low estrogen oral contraceptives |
US5418228A (en) | 1990-12-17 | 1995-05-23 | Akzo N.V. | Contraceptive regimen |
EP0491438A1 (en) | 1990-12-17 | 1992-06-24 | Akzo Nobel N.V. | Contraceptive regimen |
US5340584A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders |
EP0640343A1 (en) | 1993-07-01 | 1995-03-01 | Leiras Oy | Contraceptive for oral use containing oestradial valerate and cyproterone acetate |
DE4344462A1 (en) | 1993-12-22 | 1995-06-29 | Schering Ag | Composition for contraception |
US5583129A (en) | 1993-12-22 | 1996-12-10 | Spona; Juergen | Composition for contraception |
US5756490A (en) | 1994-03-30 | 1998-05-26 | Schering Aktiengesellschaft | Pharmaceutical combination preparation for hormonal contraception |
DE4411585A1 (en) | 1994-03-30 | 1995-10-05 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
WO1995026730A1 (en) | 1994-03-30 | 1995-10-12 | Schering Aktiengesellschaft | Combined hormonal contraception pharmaceutical preparation |
US5552394A (en) | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
EP0814803A2 (en) | 1995-03-16 | 1998-01-07 | Schering Aktiengesellschaft | Use of anti-oestrogens as male contraceptives |
US20010056086A1 (en) | 1995-03-16 | 2001-12-27 | Ursula-Friederike Habenicht | Use of anti-oestrogens as male contraceptives |
WO1998004268A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Oral contraceptive |
WO1998004246A2 (en) | 1996-07-26 | 1998-02-05 | American Home Prod | Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004269A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004267A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
WO1998004265A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
EP0917466A1 (en) | 1996-07-26 | 1999-05-26 | American Home Products Corporation | Oral contraceptive |
EP1334725A2 (en) | 1996-10-08 | 2003-08-13 | Laboratoire Theramex | Estroprogestative contraceptive composition |
EP1462107A1 (en) | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Method of female contraception and kit for use in such method |
Non-Patent Citations (132)
Title |
---|
["Corrected Citation"]: Ansbacher, Contraception, 43(2), 1991, 139-147. |
["Corrected Citation"]: Nardi et al., ActaEur.Fertil. 6(2), 1975, 153-165. (Abstract). |
0elkers et al., AAdvances in Contraception@, 7, Suppl. 3, pp. 195-206 (1991). |
A. R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, "Multicenter Clinical Trial on the new Oral Contaceptive Containing 20 μg Ethinylestradiol", Chapter 1, pp. 747-756, (1990). |
A.R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, AMulticenter Clinical Trial on the new Oral Contraceptive Containing 20 Phig Ethinylestradiol@, Chapter 1, pp. 747-756, (1990). |
A.R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, AMulticenter Clinical Trial on the new Oral Contraceptive Containing 20 Φg Ethinylestradiol@, Chapter 1, pp. 747-756, (1990). |
AHFS Drug Information 33, p. 2348, (1993). |
Andreasen, E. E. et al., "Progesterone and gestagen treatment. Pharmacologic and clinical aspects," Ugeskrift for Laeger, Aug. 7, vol. 151, No. 32, pp. 2021-2026 Abstract only. |
Ansbacher, Contraception, 43(2), 1991, 365-371. |
Archives of Gynecology and Obstetrics vol. 245, No. 1-4, 1989. |
Bachmann et al., Contraception, 70, 2004, 191-198. |
Bayer Healthcare, Patient Information Booklet for Angeliq film coated tablets, May 2008, pp. 1-12. |
Bilotta et al., "Multicenter clinical trial on the new oral contraceptive containing 20 mug ethinylestradiol," Progress in Gynecology and Obstetrics, Mar. 1989, pp. 747-756. |
Bilotta et al., "Multicenter clinical trial on the new oral contraceptive containing 20 μg ethinylestradiol," Progress in Gynecology and Obstetrics, Mar. 1989, pp. 747-756. |
Brenner, P. F. et al., "Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel," Am J Obstet Gynecol, Sep. 15, 1977, pp. 133-140. |
Bye, P. et al., "‘Missed Pill’ conception: fact or fiction?" Bristish Medical Journal, Jun. 22, 1985, vol. 290, pp. 1905. |
Calaf-Alsina et al., AObstet Gynecol@, 69, pp. 255-258, (Abstract only) (1987). |
Casals-Stenzel, J. et al., "The Renal Action of Spriorenone and other 6beta,7beta; 15beta, 16beta-dimethylene-17-spriolactones, a new type of steriodal aldosterone antagonists," Arzeneim.-Forsch./Drug Res. 34:241-246 (1984). |
Casals-Stenzel, J. et al., "The Renal Action of Spriorenone and other 6β,7β; 15β, 16β-dimethylene-17-spriolactones, a new type of steriodal aldosterone antagonists," Arzeneim.-Forsch./Drug Res. 34:241-246 (1984). |
Chemical Abstracts 76:30782, Craft et al., 1971. |
Cianci et al., Minerva Ginecol. (abstract), (Aug. 2007), 59(4), pp. 415.25. * |
Dinger, J., et al., Abstract #236, p. S104, Abstracts of the 24th ICPE, Pharmaco-epidemiology and Drug Safety 2008: 17: SI-S294. |
Drug Information of the Health Care Professional, vol. 1, USP DI 1993, 13th Edition, Chapter 50. |
Duesterberg et al., AActa Obstet Gynecol Scand Suppl@, (88), pp. 27-31, (1979). |
Düsterberg et al., AActa Obstet Gynecol Scand, Suppl.@, pp. 27-31, (1979). |
Elger et al., "Conception and pharmacodynamic profile of drospirenone." (Steroids) 2003, 891-905, 68. |
Elomaa et al., "Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment," Contraception 60, 275-279, 1999. |
Elstein et al., Zentralblatt für Gynäkologie@, pp. 559-565, (1995). |
Elstein, Advances in Contraception, 10, 1994, 1-4. |
Elstein, M.,: "Consensus paper-Low dose contraceptive formulations: is further reduction in steroid dosage justified?" Advances in Contraception, 1994; 10:1-4. |
Endrikat et al., "A twelve-month comparative clinical investigation of two lo-dose oral contraceptives containing 20 mug ethinylestradiol / 75 mug gestodene and 30 mug ethinylestradiol / 75 mug gestodene, with respect to efficacy, cacyle control, and tolerance," Contraception 55, 131-137, 1997. |
Endrikat et al., "Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 mug ethinyl estradiol and 75 mug gestodene," Contraception 69, 2, 99-105, 2001. |
Endrikat et al., "A twelve-month comparative clinical investigation of two lo-dose oral contraceptives containing 20 μg ethinylestradiol / 75 μg gestodene and 30 μg ethinylestradiol / 75 μg gestodene, with respect to efficacy, cacyle control, and tolerance," Contraception 55, 131-137, 1997. |
Endrikat et al., "Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75 μg gestodene," Contraception 69, 2, 99-105, 2001. |
Excerpts (D7) from opposition to corresponding German patent 4344462; cited in oppositions against corresponding EP patent 735883. |
Facts & Comparisons, (1985), pp. 108c-108e. |
Filshie et al. (ed.); Book: Contraception: Science and Practice; Chapter: Practical Prescribing of the Combined Oral Contraceptive Pill; Section: The Paramount Inportance of the Pill-free Interval; Butterworth-Heinemann, pp. 76-82, 1989. |
Filshie et al., (ed.); Book: Contraception: Science and Practice; Chapter: Practical Prescribing of the Combined Oral Conraceptive Pill; Section: The Paramount Importance of the Pill-free Interval; Butterworth-Heinemann, pp. 76-82, 1989. |
Fioretti et al., "Clinical and metabolic study of a new pill containing 20 mcg Ethinylestradiol plus 0.150 mg Desogestrel," Contraception, 1987, vol. 35, No. 3, pp. 229-243. |
Fitzgerald et al., "A comparison of the effects oftwo monophasic lo dose oral contraceptives on the inhibition of ovulation," Advances in Contraception 10, 5-18, 1994. |
Foidart et al., AInt=l J. Gynecol & Obstet@, 46, Suppl. 3, p. 11, (1994). |
Foster, Low-dose Monophasic and Multiphasic Oral Contraceptives: A Review of Potency, Efficacy, and Side Effects, 7(3), 1989, 205-212. |
Fruzetti et al., Contraception, 63, 2001, 303-307. |
G.B. Melis, et al., Contraception, "A Comparative Study on the Efects of a Monophasic Pill Containing Desogestrel Plus 20 μg Ethinylestradiol, a Triphasic Combination Containing Levonorgestrel and a Monophasic Combination Containign gestrodene on Coagulatory Factors", vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract]. |
G.B. Melis, et al., Contraception, AA Comparative Study on the Effects of a Monophasic Pill Containing Desogestrel Plus 20 Phig Ethinylestradiol, a Triphasic Combination Levonorgestrel and a Monophasic Combination Containing gestrodene on Coagulatory Factors@, vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract]. |
G.B. Melis, et al., Contraception, AA Comparative Study on the Effects of a Monophasic Pill Containing Desogestrel Plus 20 Φg Ethinylestradiol, a Triphasic Combination Levonorgestrel and a Monophasic Combination Containing gestrodene on Coagulatory Factors@, vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract]. |
German Pharmacopeia, 9th Edition, 1986-English Translation, p. 105. |
German Pharmacopeia, 9th Edition, 1986-English Translation. |
Gladwell, M. "John Rock's Error." (The New Yorker). Mar. 13, 2000, 52-63. |
Hayes, J.L., et al., "A Pilot Clinical Trial of Ultrasound-Guided Postplacental Insertion of Levonorgestrel IUS," Contraception/Family Planning, vol. 107, No. 4 (Supplement), Apr. 2006-1 page. |
Hess et al., Acta Pharmaceutica Technologica, 21(4) :245-54, 254, 1975. |
Holdaway et al., AActa Endocrinol@, 109, 522-529, (Abstract only) (1985). |
Huempel et al., Contraception@, 16, pp. 199-216 (Abstract only), (1977). |
J. Guillebaud, Br. J. Family Planning, 12 (Stippl.), 35-43 (1987). |
J.C. Chaumeil, Meth, Find Exp. Clin, Pharm., 20(3):211-215, 211, 1998. |
J.O. Drife, "Oral contraception for the over 40s," Annual Progress in Reproductive Medicine, 1993. |
Jandrain et al., "Am J. Obstet Gynecol", 163, pp. 378-381, (1990). |
Johnson, Clin.Obst. And Gynecol., 30:267-276 (1987). |
K. Fotherby, Contraception, 54:59-69, 61, 1996. |
Kaplan, Cardiol.Clin. 6:475-482 (1988). |
Kase, NG, Gender Medicine, (2009), 6, Part 1: 37-59. * |
Killick, S. R. et al., "Extending the duration of the pill-free interval during combined oral contraception," Advances in Contraception, 1990, vol. 6, pp. 33-40. |
Kilogest, Consumer Medicine Information, Dec. 2006, pp. 1-3. |
Klebe et al, AArch Gynecol@, 234, pp. 113-120, (Abstract only) (1983). |
Krattenmacher et al., "Effects of drospirenone on blood pressure and heart rate in rats measured by highly sensitive radio-telemetry," XVII Meeting I.S.G.S.H. Nov. 25-28, 1995, p. 55. |
Kuhl et al., AContraception@, 30, pp, 467-482, (1985). |
Kuhl, Gynäkologe, 25, 1992, 231-240. |
Kuhl, H., "Pharmacokinetics of oestrogens and progestogens," Maturitas, 1990, vol. 12, pp. 171-197. |
Kuhl, H.,: "Recent developments in hormonal contraception," Gynakologe (1992) 25: 231-240. (translation). |
Kuhnz et al., "Contraception", 48, pp. 557-575, (1993). |
Lammers et al., Acta Obstet. Gynecol. Scand., 70(6), pp. 497-500 (1991). |
Landgren, B. M. et al., "The effect on follicular growth and luteal function of ‘missing the pill’: A comparison between a monophasic and a triphasic combined oral contraceptive," Contraception, Feb. 1991, vol. 43, No. 2, pp. 149-159. |
Larsson-Cohn et al., AActa Obstet Gynecol Scand@, 65, pp. 125-128, (Abstract only) (1986). |
Laurent, H. et al., "Synthesis and Activities of Anti-Aldosterones," Steroid Biochem., 19:771-776 (1983). |
Leis et al., AGeburtshilfe Frauenheilkd@, 39, pp. 54-57 (Abstract only), (1979). |
Letterie, G. S., Effect of "Missed" Pills on Oral Contraceptive Effectiveness, Jun. 1992, vol. 79, No. 6, pp. 979-982. |
Losert et al., "Progestogens with Antimineralocorticold Activity," Arzneim.-Forsch./ Drug Res. 35, 1985, No. 2, pp. 459-471. |
M. Elstein, AAdvances in Contraception@, 12, pp. 155-156, (1996). |
Martindale, The Extra Phamacopoeia, Edited by James E.F. Reynolds, pp. 2003-2004, Thirtieth Ed. (1993). |
McInnes et al., J. Clinical Pharmacology, 22:410-17, 410-11, 1982. |
Minulet®, 1992 du Vidal. |
Molley et al., "‘Missed Pill’ conception: fact of fiction?" British Medical Journal, vol. 290, May 18, 1985, pp. 1474-1475. |
Moneva®, 1992 du Vidal. |
Muhn, P. et al., "Drosplrenone: A Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity," Annals New York Acad. Sciences, 761:311-35 (1995). |
Nakajima, S. J. et al., "Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin 24 Fe)," Contraception, 2007, vol. 75, pp. 16-22. |
Nappi et al., Contraception, 67, 2003, 355-359. |
Nardi et al., ActaEur.Fertil. 6(2), 1975, 153-165. |
Nardi, M. et al, "Cyproterone Acetate-Ethinylestradiol Treatment of Hirsutism, Acne, Seborrhea and Alopecia," Insegnamento di Endocrinologia Ginecologica, Acta Eur. Fertil 6(2), Apr. 20, 1975, pp. 153-165. |
Nickisch et al., "Aldosterone Antagonists. 4. Synthesis and Activities of Steroidal 6,6-Ethylene-15,16-methylene 17-Spiroiactones," J.Med.Chem., 34:2964-2968 (1991). |
Notice of Certification Under 21 U.S.C. § 355(j)(2)(B) (§ 505(j)(B)) of Federal Food, Drug and Cosmetic Act) and 21 C.F.R. § 314.95)—Sandoz Inc.'s Drospirenone; Ethinyl Estradiol Tablet, 3 mg; 0.02 mg—Sandoz Inc.'s ANDA 79-221, pp. 1-43. |
Oelkers et al., "Acta Endocrinologica", Suppl. 4, p. 71, #97, (1992) (Abstract only). |
Oosterbaan, Eur.J.Contracep.Repr.Health Care, 4(suppl 2), 1999, 3-8. |
Parke Davis package insert for Loestrin, Jun. 1993. |
Patent and Utility Model filed Dec. 22, 1993, re DE 4344462, translation pp. 22-23. |
PCT Search Report dated May 12, 1995. |
Pearlstein et al., "Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation." Presented at the 60th Annual Meeting of the American Society for Reproductive Medicine, Philadelphia, PA, Oct. 20, 2004, pp. 1-26. |
Petersen et al., "Effects of monophasic low-dose oral contraceptive on fibrin formation and resolution in young women," Hemostatic balance during oral contraception, Am. J. Obstet. Gynecoll, vol. 168, No. 1, part 1, pp. 32-38, Jan. 1993. |
Pollow, K. et al, "Dihydrospirorenone (ZK30595): A Novel Progestagen-Characterization of Binding to Different Receptor Proteins," Contraception 46:561-754 (1992). |
Porcile et al., "Fertility and Sterility", 55, pp. 877-881, (Abstract only) (1991). |
Runnebaum, B et al., "New progestogens in oral contraceptives," Am J Obstet Gynecol, Oct. 1987, vol. 157, pp. 1059-1063. |
Scheen et al., "Fertility and Sterility", 59, pp. 797-802, (Abstract only) (1993). |
Schillinger et al., AArzneim.-Forsch.@, 26, pp. 2242-2245, (Abstract only), (1976). |
Schneider, W. H. F. et al., "Experimental and Clinical Data on Cyclabil," Acta Obstet Gynecol Scand, 1977, Suppl 65, pp. 39-43. |
Serlaly D.: "The 20 mcg ethinylestadiol and 140 mcg Desogestrell pill: sic months, multicenter study in 235 Women," 2990, June Fertil.Contracept.Sex, 18(6): 407-12. |
Shah et al., Pharm. Tech. 152-60, 152, 1994. |
Shaw, Geoffrey et al., "Assessment of ovarian activity in a gestodene containing triphasic oral contraceptive," the British Journal of Family Planning, 1992, vol. 18, pp. 76-78. |
Smith et al., Clinical Pharmacy, 3, 1984, 485-496. |
Spielmann et al., Eur.J.Contracep.Repr.Health Care, 4(suppl 2), 1999, 17-25. |
Spielmann et al., Eur.J.Contracep.Repr.Health Care, 4(suppl 2), 1999, 9-15. |
Spona et al., "Gynecol Obstet Invest", 23, pp. 184-193, (1987). |
Spona et al., "Shorter pill-free interval in combined oral contraceptives decreases follicular development" Contraception 54, 71-77, 1996. |
Spona, J et al., "Inhibition of ovulation by a triphasic gestodene-containing oral contraceptive," Advances in Contraception, 1993, vol. 9, pp. 187-194. |
Spona, J. et al., "Pharmacological and endocrine profiles of gestodene," Int. J. Fertil., 1987, 32 Suppl: 6-14. |
Sulak, P.J., et al., "Extended Regimen Oral Contraceptives-Practical Management," Clinical Update-Supplemental to OBG Management, Jan. 2007, S1-S8. |
Sullivan et al., "Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 mug (and ethinyl estradiol (15 mug) on ovarian activity," Fertility and Sterility 72, 1, 115-120, 1999. |
Sullivan et al., "Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg (and ethinyl estradiol (15 μg) on ovarian activity," Fertility and Sterility 72, 1, 115-120, 1999. |
Szapiro, C.R.Ther.Pharmacol.Clin, 112, 1993, 3-7. |
The Merck Manual, 17th edition (1999), pp. 1973-74; 1932. * |
Theramex, "Estroprogestative Contraception Composition," Publication Date: Feb. 14, 2007, Retrieved from espacenet.com on May 28, 2010; English Abstract of EP 1 334 725. |
Translation of DE 3022337. (Jan. 1982). |
Translation of EP 0398460 A2, Application No. 90250127.9, filed May 16, 1990; (pub. Nov. 1990). |
Translation of Minulet®, 1992 du Vidal. |
Translation of Monevat®, 1992 du Vidal. |
Translation of Szapiro, C.R.Ther.Pharmacol.Clin., 112, 1993, 3-7. |
Tuimala R. et al.: "A Clinical comparison in Finland of two oral contraceptives containing 0,150 mg Desogestrel in combination with 0,020 mg or 0,030 mg ethinyiestradil," Acta Obstet Gynecol Scand Suppl, 1987, 1477:7-12. |
Van Keep et al., eds. AThe Controversial Climactoric@, MTP Press Limited, 9-18 (1981). |
W. Oelkers et al., AActa Endocrinologica@, Suppl. 4, p. 71, #97, (1992) (Abstract Only). |
W. Oelkers et al., AJournal of Clinical Endocrinology and Metabolism@, 80, pp. 1816-1821, (1995). |
W. Oelkers et al., AJournal of Clinical Endocrinology and Metabolism@, p. 73, pp. 837-842, (1991). |
Wang et al., "Treatment of premenstrual sydrome by spironolactone: A double-blind, placebo-controlled study," Acta Obstet.Gynecol.Scand., 74: 803-808 (1995). |
Willis, S.A., et al., "Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval," Contraception 74(2006), pp. 100-103. |
Zacur et al., Current Opinion in Obstetrics and Gynecology, 4, 1991, 365-371. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11376263B2 (en) | 2020-10-08 | 2022-07-05 | Fortress Biotech, Inc. | Cyproterone acetate compositions and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE44159E1 (en) | Composition for contraception | |
US6312722B1 (en) | Pharmaceutical combined preparation, kit and method for hormonal contraception | |
US5756490A (en) | Pharmaceutical combination preparation for hormonal contraception | |
US5980940A (en) | Pharmaceutical combination preparation for hormonal contraception | |
CA2301162A1 (en) | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin | |
AU2152799A (en) | Progestogen-antiprogestogen regimens | |
AU722362B2 (en) | Pharmaceutical combination preparation for hormonal contraception | |
AU726283B2 (en) | Pharmaceutical combined preparations, kit and method for hormonal contraception | |
MXPA96004440A (en) | Preparation of a pharmaceutical combination for oven contraception | |
MXPA98000026A (en) | Combined pharmaceutical preparation, equipment and method for hormo contraception |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction |